Immunotherapy of Recurrent Genital Herpes with Recombinant Herpes Simplex Virus Type 2 Glycoproteins D and B: Results of a Placebo-Controlled Vaccine Trial

To determine the safety, immunogenicity, and efficacy of a recombinant herpes simplex virus type 2 glycoprotein D and B vaccine in the treatment of recurrent genital herpes, a randomized, placebo-controlled trial was held at two referral centers. Healthy patients with 4–14 recurrences per year recei...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 1997-11, Vol.176 (5), p.1129-1134
Main Authors: Straus, S. E., Wald, A., Kost, R. G., McKenzie, R., Langenberg, A. G. M., Hohman, P., Lekstrom, J., Cox, E., Nakamura, M., Sekulovich, R., Izu, A., Dekker, C., Corey, L.
Format: Article
Language:English
Subjects:
Adult
Antibodies, Viral - blood
Biological and medical sciences
Double-Blind Method
Female
Fundamental and applied biological sciences. Psychology
Herpes Genitalis - therapy
Herpesvirus 2, Human - immunology
Humans
Male
Microbiology
Middle Aged
Recombinant Proteins - immunology
Recurrence
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies
Vaccines, Synthetic - immunology
Viral Envelope Proteins - immunology
Viral Vaccines - adverse effects
Viral Vaccines - therapeutic use
Virology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To determine the safety, immunogenicity, and efficacy of a recombinant herpes simplex virus type 2 glycoprotein D and B vaccine in the treatment of recurrent genital herpes, a randomized, placebo-controlled trial was held at two referral centers. Healthy patients with 4–14 recurrences per year received injections of both glycoproteins in MF59 adjuvant or of MF59 alone at 0, 2, 12, and 14 months. For 18 study months, the rate and number of recurrences, the duration and severity of the first confirmed recurrence, vaccine immunogenicity, and rates of local and systemic reactions were determined. The monthly rate of recurrences was not significantly improved, but the duration and severity of the first study outbreak was reduced significantly by vaccination. Glycoproteinspecific and neutralizing antibodies were boosted by vaccination for the duration of the study. This vaccine is safe and immunogenic and ameliorated an observed first postvaccination genital recurrence, but it does not reduce recurrence frequency.
ISSN:0022-1899
1537-6613
DOI:10.1086/514103